HCA
failedHCA Healthcare, Inc.
Price Chart
Gap Information
Score Analysis
Model 1: Rerate Score
Model 2: Trade Probability
AI Thesis
HCA Healthcare's 7.3% gap-up likely reflects a combination of earnings beat, labor cost normalization, and raised guidance that collectively force the Street to re-rate the largest for-profit hospital operator. Wall Street has been preoccupied with structural labor inflation and managed care pricing pressures, but HCA's results would demonstrate that same-facility admissions growth and pricing power are offsetting cost headwinds better than feared. The volume of contract labor — a major margin drag over the past two years — appears to be normalizing faster than expected, unlocking operating leverage that management can quantify in raised forward guidance. The re-rating thesis rests on HCA's ability to sustain mid-to-high single-digit revenue growth while expanding margins back toward pre-COVID levels. With the stock trading at roughly 12-14x forward earnings — a discount to historical averages despite a durable competitive moat in high-acuity urban markets — even modest guidance increases can catalyze multiple expansion. Additionally, HCA's consistent capital return program through buybacks compounds the repricing effect, as fewer shares amplify EPS growth visibility.
Analyzed by rerate-v2+glm-5.2 · Jul 29, 2026
Catalysts
- Labor cost normalization with contract labor expenses declining year-over-year, improving operating margins
- Raised full-year 2024 guidance on both revenue and EPS, signaling management confidence
- Strong same-facility admissions and revenue growth indicating market share gains and demographic tailwinds
- Robust free cash flow generation supporting continued aggressive share repurchases
- Managed care pricing remaining favorable with limited payer pushback on rate increases
- Potential for further multiple expansion as investor sentiment shifts from cost fears to margin recovery narrative
Risks
- Commercial payer pressure and potential pushback on rising hospital pricing could compress revenue per admission
- Ongoing nurse union activity and wage inflation in key markets could reignite labor cost concerns
- Medicare Advantage payor mix deterioration as MA enrollment grows, pressuring reimbursement rates
- Regulatory scrutiny on charity care and billing practices, particularly given HCA's for-profit status
- Macroeconomic slowdown could defer elective procedures, though historically hospital demand is recession-resilient
- High debt load and rising interest costs could constrain capital allocation flexibility
Technical Setup
Forward Returns
Outcomes calculated Aug 11, 2026
Post-Gap Validation — 5-Day Follow-Through
Day-by-Day Price Action
| Day | Close | High | Low | Volume |
|---|---|---|---|---|
| Day 1 | $395.79 | $406.76 | $394.74 | 1.24M |
| Day 2 | $402.59 | $404.52 | $391.38 | 1.26M |
| Day 3 | $406.61 | $415.62 | $402.28 | 1.18M |
| Day 4 | $400.73 | $403.92 | $395.56 | 1.32M |
| 📍 Day 5 | $409.64 | $411.45 | $399.75 | 1.12M |
Signal Breakdown
Gap 75% filled — price gave back most of the post-earnings gap
Volume sustained — only 10% decline suggests continued accumulation
Higher highs with peak close on day 5 — continued buying interest
Moderate drawdown (5.5%)
No fundamental data to evaluate beat quality
Analysis updated Aug 11, 2026